Emcure cuts Poviztra starting dose price by 55% to ₹3,999
Emcure just dropped the price of the starting dose of its obesity drug Poviztra by 55%, making it much more affordable at ₹3,999 per month.
This big cut comes after the semaglutide patent expired in India and follows similar moves by Novo Nordisk with Wegovy and Ozempic.
The new pricing kicks in from April 3, 2026.
Emcure positions Poviztra against generics
With India facing a major obesity crisis (hundreds of millions affected), Emcure is positioning Poviztra to compete with new low-cost generics hitting the market.
CEO Satish Mehta says they're The revised pricing of Poviztra is a step toward making scientifically validated weight-management therapies more accessible and affordable to a wider patient base.
and hopes this price drop helps more people get effective treatment when it matters most.